Artículo
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
Autor/es | Cruz Merino, Luis de la
Gion, M. Cruz, J. Alonso-Romero, J. L. Quiroga, V. Moreno, F. Jiménez Cortegana, Carlos Sánchez Margalet, Víctor Rojo, F. |
Departamento | Universidad de Sevilla. Departamento de Medicina Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología |
Fecha de publicación | 2023 |
Fecha de depósito | 2023-10-06 |
Publicado en |
|
Resumen | Background: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody
pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients
previously ... Background: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential synergism that could eventually obtain long term beneft in these patients. Methods: HER2-negative ABC patients received 21-day cycles of pembrolizumab 200 mg (day 1) and gemcitabine (days 1 and 8). A run-in-phase (6+6 design) was planned with two dose levels (DL) of gemcitabine (1,250 mg/m2 [DL0]; 1,000 mg/m2 [DL1]) to determine the recommended phase II dose (RP2D). The primary objective was objec‑ tive response rate (ORR). Tumor infltrating lymphocytes (TILs) density and PD-L1 expression in tumors and myeloidderived suppressor cells (MDSCs) levels in peripheral blood were analyzed. Results: Fourteen patients were treated with DL0, resulting in RP2D. Thirty-six patients were evaluated during the frst stage of Simon’s design. Recruitment was stopped as statistical assumptions were not met. The median age was 52; 21 (58%) patients had triple-negative disease, 28 (78%) visceral involvement, and 27 (75%)≥2 metastatic locations. Progression disease was observed in 29 patients. ORR was 15% (95% CI, 5–32). Eight patients were treated≥6 months before progression. Fourteen patients reported grade≥3 treatment-related adverse events. Due to the small sample size, we did not fnd any clear association between immune tumor biomarkers and treatment efcacy that could identify a subgroup with higher probability of response or better survival. However, patients that experienced a clini‑ cal beneft showed decreased MDSCs levels in peripheral blood along the treatment. Conclusion: Pembrolizumab 200 mg and gemcitabine 1,250 mg/m2 were considered as RP2D. The objective of ORR was not met; however, 22% patients were on treatment for≥6 months. ABC patients that could beneft of chemoimmunotherapy strategies must be carefully selected by robust and validated biomarkers. In our heavily pre‑ treated population, TILs, PD-L1 expression and MDSCs levels could not identify a subgroup of patients for whom the combination of gemcitabine and pembrolizumab would induce long term beneft. Trial registration: ClinicalTrials.gov and EudraCT (NCT03025880 and 2016–001,779-54, respectively). Registration dates: 20/01/2017 and 18/11/2016, respectively. |
Cita | Cruz Merino, L.d.l., Gion, M., Cruz, J., Alonso-Romero, J.L., Quiroga, V., Moreno, F.,...,Rojo, F. (2023). Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study. BMC CANCER, 22 (1). https://doi.org/10.1186/s12885-022-10363-3. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Pembrolizumab...pdf | 1.573Mb | [PDF] | Ver/ | |